Data from a phase 3 trial of Teva Pharmaceutical Industries' (NYSE:TEVA) TEV-'749 indicated that the long-acting, subcutaneous version of the antipsychotic olanzapine led to improvement in social functioning and quality of life through week 8.

In addition, no instances of post-injection delirium/sedation syndrome have been reported to date.

The SOLARIS study Period 1 is an 8-week, randomized, double-blind, placebo-controlled trial in adults with schizophrenia from 18-64 years old. Period 2 is an open-label safety period of up to 48 weeks.

In Period 1, improvement in social functioning and quality of life was seen in all three doses tested.

The mean differences in change in the Personal and Social Performance Scale, from baseline to week 8 were all higher with all TEV-'749 doses compared to placebo: 318mg (4.63), 425mg (3.15), and 531mg (4.93).

Improvement in Schizophrenia Quality of Life Scores over the same period was as follows: 318mg (-3.99), 425mg (-5.39), and 531mg (-5.65). All were better than what was seen in the placebo group.

Separately, Teva released data from real-world analyses of Uzedy, its subcutaneous long-acting injectable of risperidone. Results showed high adherence rates in adults with high unmet social needs.